Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-1,227
Closed -$434K 216
2018
Q3
$434K Sell
1,227
-2,923
-70% -$1.01M 0.02% 171
2018
Q2
$1.2M Buy
4,150
+3,030
+271% +$852K 0.05% 125
2018
Q1
$307K Sell
1,120
-6
-0.5% -$1.86K 0.01% 196
2017
Q4
$359K Buy
1,126
+190
+20% +$61K 0.01% 183
2017
Q3
$293K Buy
936
+6
+0.6% +$1.78K 0.01% 191
2017
Q2
$252K Sell
930
-7
-0.7% -$1.85K 0.01% 191
2017
Q1
$256K Sell
937
-68
-7% -$19.2K 0.01% 194
2016
Q4
$285K Sell
1,005
-200
-17% -$59.3K 0.01% 188
2016
Q3
$377K Hold
1,205
0.02% 165
2016
Q2
$291K Sell
1,205
-630
-34% -$166K 0.01% 175
2016
Q1
$478K Buy
1,835
+291
+19% +$76.9K 0.02% 145
2015
Q4
$473K Buy
1,544
+10
+0.7% +$2.87K 0.02% 150
2015
Q3
$448K Buy
1,534
+731
+91% +$241K 0.02% 154
2015
Q2
$324K Buy
803
+13
+2% +$5.22K 0.02% 157
2015
Q1
$334K Buy
790
+141
+22% +$55.6K 0.02% 158
2014
Q4
$220K Buy
649
+5
+0.8% +$1.62K 0.01% 175
2014
Q3
$213K Buy
+644
New +$212K 0.01% 184

Other funds holding BIIB

R.M. Davis Inc's BIIB Position: Q4 2018 in Review

R.M. Davis Inc sold out of Biogen (BIIB) in Q4 2018, closing a stake of 1,227 shares — an estimated $434K sold.

R.M. Davis Inc first reported a position in BIIB in Q3 2014 and held it in 17 quarters. The position peaked at $1.2M in Q2 2018. 1,141 funds tracked by Wall St. Rank hold BIIB as of Q4 2018.

  • R.M. Davis Inc reported no remaining Biogen position as of Q4 2018 after selling out during the quarter.
  • R.M. Davis Inc sold 1,227 Biogen shares in Q4 2018, an estimated $434K.
  • R.M. Davis Inc first reported a position in Biogen in Q3 2014 and held it in 17 quarters.
  • R.M. Davis Inc's Biogen position peaked at $1.2M in Q2 2018.
  • 1,141 funds tracked by Wall St. Rank held Biogen as of Q4 2018.

Based on R.M. Davis Inc's 13F filing for Q4 2018, filed 18 Jan 2019.